Thailand Attention Deficit Hyperactivity Disorder Therapeutic Market Report 2022 to 2030

Thailand ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Analysis

$ 3999

Thailand's Attention Deficit Hyperactivity Disorder (ADHD) therapeutics market is expected to witness growth from $35 Mn in 2022 to $65 Mn in 2030 with a CAGR of 7.84% for the year 2022-30. The increase in the disposable incomes of the population in Thailand and the rising demand for effective treatment options for ADHD in Thailand are propelling the market growth. The Thailand ADHD therapeutics market is segmented by drug, drug type, demographics, and by distribution channel. Some of the leading companies in the market are Healol Pharmaceuticals, Sriprasit Pharmacy, and Prude Pharma.

ID: IN10THPH028 CATEGORY: Pharmaceuticals GEOGRAPHY: Thailand AUTHOR: Parul Choudhary

Buy Now

Thailand Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Executive Analysis

The Thailand Attention Deficit Hyperactivity Disorder (ADHD) therapeutics market size is at around $35 Mn in 2022 and is projected to reach $65 Mn in 2030, exhibiting a CAGR of 7.84% during the forecast period. The National Health Security Office is asking for a $5.96 Bn budget in order to include Covid-19 testing and treatment in the advantages of universal healthcare in Thailand for 2023. Upgrades to the universal healthcare system's services, a telemedicine program, and the promotion of medicinal cannabis are all planned to be covered by the budget for the 2023 fiscal year. Additionally, it allocates funds for the Government Pharmaceutical Organization to buy immunizations, medications, and medical equipment. The proposed budget would give $1.48 Bn to the National Health Security Fund and $1.78 Bn to cover salary expenses.

One of the most prevalent neurodevelopmental diseases with childhood onset is Attention Deficit Hyperactivity Disorder (ADHD). Between 0.1 and 8.1% of people globally are thought to have ADHD. Its prevalence in Thailand was determined to range from 4.2 to 8.1%. According to recent studies, ADHD is brought on by a lack of a few key brain chemicals, with genetics playing a significant role. About 30–40% of kids with attention deficit hyperactivity disorder (ADHD) will also have an ADHD-afflicted family relative. A mother who is malnourished and consumes alcohol, smokes, or consumes certain pollutants like lead while pregnant are more likely to give birth to a child who has attention deficit hyperactivity disorder. (ADHD).

A class of drugs known as psychostimulants, including methylphenidate (Ritalin®), long-acting methylphenidate (Concerta®), or non-psychostimulants like atomoxetine (strattera®), are the most efficient treatments used in Thailand for attention deficit hyperactivity disorder (ADHD). These medications are effective in treating their patients and secure, with few side effects. Drugs will make the child more focused, less hyperactive, calmer, and less impulsive, which may improve learning ability. The child will experience improved self-esteem and better relationships with friends or those around him/her as a result of getting appropriate treatment.

thailand attention deficit therapeutics market

Market Dynamics

Market Growth Drivers

There is a rising need for efficient treatments as both the general public and healthcare professionals become more conscious of ADHD. The demand for medication and therapy is rising as more individuals seek an ADHD diagnosis and treatment. The rising prevalence of ADHD and the greater understanding of its symptoms are driving up demand for Thailand's ADHD therapeutics market. Sales of ADHD medications have grown as a result of a large number of patients searching for efficient treatments to control their symptoms. Thailand's middle class has more disposable money as a result of the country's expanding economy. As a result, there is an increase in demand for healthcare services, including treatment for ADHD.

Market Restraints

For some patients, especially those with limited resources, the cost of ADHD medications and therapies can be a barrier to treatment. As a result, there may be less of enthusiasm for ADHD treatments, which could slow the Thailand ADHD therapeutics market expansion. Alternative treatments for ADHD, like herbal remedies or behavioral interventions, may be preferred by some patients. This may restrict the market's expansion for conventional ADHD drugs and treatments.

Competitive Landscape

Key Players

Better Pharma (THA)
Thai Meiji Pharmaceutical (THA)
Interthai Pharmaceutical (THA)
Healol Pharmaceuticals (THA)
Sriprasit Pharmacy (THA)
Prude Pharma
NEOS Therapeutics
Amneal Pharmaceuticals
Janssen Pharmaceuticals
Noven Pharmaceuticals
RespireRx Pharmaceuticals
Otsuka Pharmaceutical

Healthcare Policies and Regulatory Landscape

Food, food supplements, medications, devices, and devices used for general and specific consumption that are used for health reasons must register with the Ministry of Public Health, comply with registration standards, and receive Thailand Food And Drug Administration (Thai FDA) approval prior to distribution. Health goods are divided into six different groups by the FDA Thailand, including drugs (or psychotropic substances), food and food additives, narcotics, hazardous substances (or volatile substances), and cosmetic or medical devices. For sellers to legally promote and distribute it to consumers while guaranteeing its standard, it must go through the required processes of validation and registration. For its secure distribution to the market, scientific research is conducted. To make sure that food, drugs, cosmetics, and medical devices continue to adhere to safety and quality standards, the Thai FDA observes and performs surveillance on these products. The Thai FDA has the authority to impose sanctions on producers and distributors who disobey laws or standards for safety and quality.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Segmentation

By Drug Type (Revenue, USD Billion):

Stimulants
- Amphetamine
- Methylphenidate
- Dextroamphetamine
- Dexmethylphenidate
- Lisdexamfetamine
- Others
Non-Stimulants
- Atomoxetine
- Bupropion
- Guanfacine
- Clonidine

By Age Group (Revenue, USD Billion):

Pediatric And Adolescent
Adult

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Speciality Clinics
Retail Pharmacies
e-Commerce

By Psychotherapy (Revenue, USD Billion):

Behaviour Therapy
Cognitive Behavioral Therapy
Interpersonal Psychotherapy
Family Therapy

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.